Home Medizin Eine bestimmte Art der Chemotherapie verbessert nachweislich die Fähigkeit des Immunsystems, Blasenkrebs abzuwehren

Eine bestimmte Art der Chemotherapie verbessert nachweislich die Fähigkeit des Immunsystems, Blasenkrebs abzuwehren

von NFI Redaktion

Researchers at the Tisch Cancer Institute have found that a specific type of chemotherapy enhances the immune system’s ability to combat bladder cancer, especially when combined with immunotherapy, as reported in a study published in Cell Reports Medicine in January.

These findings could explain why the approach of cisplatin chemotherapy can lead to a cure in a small subset of patients with metastatic or advanced bladder cancer. The researchers also believe that their results could explain why clinical trials combining a different type of chemotherapy, carboplatin-based chemotherapy, with immunotherapy were not successful, while those combining cisplatin with immunotherapy were successful.

We have known for decades that cisplatin is more effective in bladder cancer than carboplatin. The mechanisms underlying these clinical observations, however, have been unclear. This study provides clues as to why cisplatin-based chemotherapy can achieve sustained disease control in a subset of patients with metastatic bladder cancer, provides evidence for which patients might benefit from such an approach, and lays the groundwork for the development of even better treatment regimens that leverage the immunomodulatory effects of cisplatin-based chemotherapy.

Matthew Galsky, MD, lead author of the study, Co-Director of the Bladder Cancer Center at the Tisch Cancer Institute at Mount Sinai

Approximately 83,000 people in the United States are affected by bladder cancer each year. Metastatic bladder cancer is particularly difficult to cure with current treatment methods. Therefore, these findings are an important step towards using the available medications as effectively as possible and identifying effective combination therapies.

The study found that chemotherapy with cisplatin may be more effective when the body has already generated a pre-existing, but restrained, immune response to the tumor. The study also revealed that cisplatin damages the DNA in cancer cells, which could lead to changes in gene expression that enhance the body’s immune system’s ability to recognize cancer cells.

This research was part of a large scientific collaboration, using biopsies from an international clinical phase-3 study involving multiple institutions. This study was funded by Genentech.


Mount Sinai Health System

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.